.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
BioShockers Alert
Picked up some SNSS @ $1.03
I don't believe the company is dead. The main reason it had board activity was b/c of the potential merger w/ LJPC. When that fell through, most dumped ADMP...
ADMP has a lot of future potential, and could be a nice, long-term growth stock, IMO...
JMO/DYODD
GL!
Welcome as new assistant mod!
Hana Biosciences Completes Pre-NDA Meeting With FDA for Marqibo in Adult Acute Lymphoblastic Leukemia
8:30 AM ET 4/27/10 | GlobeNewswire
Hana Biosciences (OTCBB:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that the Company has completed a pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA) related to its lead product candidate, Marqibo for the treatment of relapsed/refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL). The purpose of the meeting was to discuss the proposed NDA and to confirm the clinical, non-clinical and manufacturing requirements for the NDA submission.
Following the pre-NDA meeting, Hana intends to proceed with its plan to submit a rolling NDA for Marqibo in relapsed/refractory adult Philadelphia chromosome-negative ALL.
About Marqibo(R) (vincristine sulfate liposomes injection)
Marqibo is a novel, targeted, Optisome(TM) encapsulated formulation of vincristine sulfate, a widely-used chemotherapy, which has shown promising anti-cancer activity in patients with ALL, non-Hodgkin's lymphoma, Hodgkin's disease, and melanoma in several clinical trials. Marqibo is designed to enhance the penetration and concentration of vincristine sulfate at sites of active cancer and facilitate dose-intensification compared to standard vincristine formulations. Unlike standard vincristine, Marqibo is dosed based on actual patient body surface area without the need for dose-capping.
Hana Biosciences has received orphan drug and fast track designations for Marqibo for the treatment of adult ALL from the U.S. Food and Drug Administration. Marqibo has also received orphan drug designation in adult ALL from the European Medicines Evaluation Agency.
About Hana Biosciences
Hana Biosciences, Inc. is a biopharmaceutical company dedicated to developing and commercializing new, differentiated cancer therapies designed to improve and enable current standards of care. The company's lead product candidate, Marqibo(R), potentially treats acute lymphoblastic leukemia and lymphomas. The Company has additional pipeline opportunities, some of which, like Marqibo, improve delivery and enhance the therapeutic benefits of well characterized, proven chemotherapies and enable high potency dosing without increased toxicity. Additional information on Hana Biosciences can be found at www.hanabiosciences.com.
The Hana Biosciences, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3290
Forward-Looking Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are often, but not always, made through the use of words or phrases such as "anticipates," "expects," "plans," "believes," "intends," and similar words or phrases. These forward-looking statements include without limitation, statements regarding, the timing, progress and anticipated results of Hana's planned NDA filing relating to Marqibo, including whether such NDA submission will be accepted for review or approved by the FDA; and statements regarding the potential of Marqibo to replace existing therapies and the expected benefits Marqibo may have for patients with relapsed ALL compared to existing therapies. Such statements involve risks and uncertainties that could cause Hana's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurances that any of Hana's clinical and regulatory development efforts relating to Marqibo will be successful; that even if an NDA for Marqibo is accepted by the FDA, that it will be approved; that the data of the clinical trials of Marqibo will be sufficient to support approval by the FDA of an NDA for Marqibo; that Hana will have completed all other activities necessary for the filing of an NDA or other submission with the FDA; that the results of the clinical trials of Marqibo will support Hana's claims or beliefs concerning Marqibo's safety and effectiveness; and that Hana will be able to secure the additional capital necessary to fund the activities required to complete the proposed NDA submission and other clinical and regulatory activities relating to Marqibo. Additional risks that may affect such forward-looking statements include Hana's need to raise additional capital to fund its product development programs, including Marqibo, to completion, Hana's reliance on third-party researchers to develop its product candidates, and its lack of experience in developing and commercializing pharmaceutical products. Additional risks are described in the company's Annual Report on Form 10-K for the year ended December 31, 2009. Hana assumes no obligation to update these statements, except as required by law.
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: Hana Biosciences, Inc.
CONTACT: Hana Biosciences, Inc.
Investor & Media Contacts:
Investor Relations Team
(650) 588-6641
investor.relations@hanabiosciences.com
Burns McClellan
Rebecca Birbach
(212) 213-0006
rbirbach@burnsmc.com
BioShockers Alert
Added more HNAB @ 0.343.
Judging from what it did last year going into ASCO (http://finance.yahoo.com/q/hp?s=HNAB.OB&a=04&b=29&c=2009&d=05&e=9&f=2009&g=d), I'd like to see them break the 52wk high of $1 since they are so close to an NDA filing... But the most conservative price would probably be ~.60-.70.
Thank you!
Would you mind making me assistant mod?
Thanks!
Nabi Biopharmaceuticals Announces First Quarter 2010 Financial Results Release Date
ROCKVILLE, Md., April 26, 2010 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI - News) today announced that it will report its first quarter 2010 financial results on Thursday, May 6, 2010, after market close. The company will host a live webcast at 4:30 p.m. EDT that day to discuss these results.
The live webcast can be accessed at:
http://phx.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&c=100445&eventID=3037557
(Due to the length of this URL, it may be necessary to copy and paste this hyperlink into your browser. Remove the space if one exists.) or via the Nabi Biopharmaceuticals website at http://www.nabi.com.
If you do not have Internet access, the U.S./Canada call-in number is 866-713-8564 and the international call-in number is 617-597-5312. The passcode is 81034358. An audio replay will be available through May 13, 2010 for U.S./Canada callers at 888-286-8010 and for international callers at 617-801-6888. The replay passcode is 12896767.
The press release and an archived version of the webcast will be available on the company's website at http://www.nabi.com.
About Nabi Biopharmaceuticals
Nabi Biopharmaceuticals leverages its experience and knowledge in powering the immune system to develop products that target serious medical conditions in the areas of nicotine addiction and gram-positive bacterial infections. Nabi Biopharmaceuticals is currently developing NicVAX(R) (Nicotine Conjugate Vaccine), an innovative and proprietary investigational vaccine for treatment of nicotine addiction and prevention of smoking relapse. The company is headquartered in Rockville, Maryland. For additional information about Nabi Biopharmaceuticals, please visit http://www.globenewswire.com/newsroom/ctr?d=189758&l=6&a=www.nabi.com&u=http%3A%2F%2Fwww.nabi.com
HNAB is really moving today... Great volume for only an hour after open!
GLTA.
Good morning all!
No problem!
Attention BioShockers Board: We now have a website...
www.bioshockers.com
Fully functional FDA & Clinical Trials calendar, blog, stock research section, etc...
Check it out...
Thanks for posting!
Welcome thommygun88 as new assistant moderator for "BioShockers"!
Attention: portfolio tracker is now in the iBox
Do your own DD before investing!
GLTA.
BioShockers 2Q Watch List (updated)
RNN – release of Zoraxel P2a results
QCOR – advisory committee meeting scheduled for Acthar (drug for treatment of infantile spasms) on May 6
POZN – PDUFA date for VIOMOVO on 4/30
CYTX – APOLLO and PRECISE trial results to be presented at meeting on May 7
HRBR – release of Triolex P2 results in obese type 2 diabetes patients
BNVI – possible partner for Menerba
IVD – possible FDA decision on MAGO4S 510K submission
THTCF.PK (also on Toronto exchange: TH.TO) – advisory committee meeting on May 27
PTN - Potential partner for CHF drug.
HNAB.OB - potential runup in anticipation of ASCO presentation.
To all - please do your own DD before investing. This post is just a starting point for your own DD.
GLTA.
Good news...
This stock has had a pretty nice run up from .40... Congrats to all who were in it!
Please add yourself to the BioShockers email list.
To do this:
Click "Show iBox"
At the bottom of the iBox there will be a link that says "sign up for email alerts", click that, enter in your email, and you're good to go!
Everyone have a great weekend, and if you happen to have time, check the board! It should be 100% complete (w/ watch list and all) by Sunday night!
A lot of events are coming up in June for biotech companies... SNSS, HNAB, AEZS, CYCC, and the list goes on... Will be posting a fresh watchlist for the quarter this weekend along w/ seperate DD posts for each stock.
Thanks! I agree 100%... If you have any suggestions for the board, let me know!
2010 ASCO (American Society of Clinical Oncology) Annual Meeting is June 4-8, 2010 in Chicago, IL.
http://chicago2010.asco.org/
DNDN PDUFA date is coming up soon... If Provenge receives FDA Approval, a lot of these biotechs w/ cancer drugs could see a nice boost, IMHO.
GLTA.
Called DCTH back in $5s, now in 12s and they announce positive phase 3 data a few days back... Stay tuned to this board for more awesome picks like DCTH... From now on, whenever I alert a stcok, I'll be posting DD w/ the stock.
As always, do your own DD as well.
GLTA.
greggor,
Haven't seen you around in a while! How are things going?
Soon to have a portfolio tracker in the iBox... Will post current holdings...
GLTA.
Will be updating the 2Q watch list this weekend...
GLTA.
BioShockers board:
Please tell friends/other members on iHub about this board! 2010 is going to be a fantastic year!
GLTA.
Been following HNAB for quite some time... Opened an initial position yesterday; will look to add some more next week. ASCO will be big for Hana, IMO.
GLTA.
Webcast Alert: Heska Corporation's Annual Meeting of Stockholders Webcast
LOVELAND, Colo., April 23 /PRNewswire-FirstCall/ -- Heska Corporation (Nasdaq:HSKA - News) announces the following Webcast:
What:
Heska Corporation Invites You to Listen to Its Annual Meeting of Stockholders on the Web
When:
Tuesday, May 4, @ 9:00 a.m. (MDT)
Where:
www.heska.com (click on the Annual Meeting of Stockholders link on the front page of this website)
How:
Live over the Internet -- Simply log on to the web at the address above.
Contact:
Contact – General Information: Yvonne Mulley, 970-493-7272 yvonne.mulley@heska.com
Media Contact: Jason Napolitano, 970-493-7272 jason.napolitano@heska.com
(Logo: http://www.newscom.com/cgi-bin/prnh/20000622/HESKALOGO)
If you are unable to participate during the live webcast, the call will be archived at http://www.heska.com/ until May 18, 2010. To access the replay, click on the Annual Meeting of Stockholders link on the front page of this website.
Heska Corporation (NASDAQ:HSKA - News) sells advanced veterinary diagnostic and other specialty veterinary products. Heska's state-of-the-art offerings to its customers include diagnostic instruments and supplies as well as single use, point-of-care tests, vaccines and pharmaceuticals. The company's core focus is on the canine and feline markets where it strives to provide high value products and unparalleled customer support to veterinarians. For further information on Heska and its products, visit the company's website at http://www.heska.com/.
(Minimum Requirements to listen to broadcast: The Windows Media Player software, downloadable free from http://www.microsoft.com/windows/windowsmedia/default.aspx and at least a 28.8 kbps connection to the Internet. If you experience problems listening to the broadcast, send an email to webcastsupport@tfprn.com.)
Link to major holders: http://finance.yahoo.com/q/mh?s=QCOR+Major+Holders
GLTA.
Earnings are supposed to be out next week...
GLTA.
Awesome move these past few days...
Great time to add here, IMO... Wish I had some free cash.
GLTA EntreMed longs!
Yeah, very nice! SNT has a lot going for it in the next few months, IMO.
GLTY.
Great call on ACUR!
Welcome as new assistant mod!
Which trial results are expected for SPPI on 4/30?
Thanks!